Study demonstrates that elicited repetitive daily blindness is a clinical feature in patients with familial hemiplegic migraine 3 because of gain-of-function Nav1.1 variants. Patients in this report responded to sodium channel blocker medications.
This website uses a security service to protect against malicious bots. This page is displayed while the website verifies you are not a bot.
https://doi.org/10.1172/jci.insight.203645 Here, Aaron A.R. Tobian & team use this method to evaluate antibody repertoires in kidney donors with and without HIV, reporting that antibodies against adenovirus infection in kidney donors with HIV may be associated with allograft rejection.
2Department of Pathology, School of Medicine, and.
3Department of Medicine, School of Medicine, The Johns Hopkins University, Baltimore, Maryland, USA.
4Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Atomic clocks use the quantum energy levels of atoms to tell time more accurately and precisely than any other kind of clock. (Learn more about how atomic clocks work.)
But atomic clocks can be used for more than timekeeping. They can serve as quantum sensors. Indeed, companies already use portable atomic clocks to detect oil deposits under the ocean. As these clocks become even more accurate and precise, their sensing capabilities become increasingly powerful.
To understand how atomic clocks work as sensors, we need to know a bit about Einstein’s theory of general relativity. Relativity tells us that time ticks more slowly in stronger gravity. Here on Earth, for example, a clock ticks slightly more slowly at sea level than it would on the top of a mountain, because gravity is stronger at sea level. For similar reasons, clocks in space speed up relative to those on Earth.
Pathways that favor the balance of immune cells toward those with healing potential offer therapeutic promise following injury. Here, Lynch at al. show that treatment with IL-4 expands pro-reparative macrophages through proliferation while driving concurrent death of their more inflammatory precursors, resulting in accelerated hepatic repair following acute liver injury.
Open Access.
Zheng, Y., Giri, S., Zhang, J. et al. Nat Immunol (2026). https://doi.org/10.1038/s41590-026-02509-3 Abstract Allergic asthma is driven by type 2 immune responses, including type 2 innate lymphoid cells (ILC2s). Although ILC2s are activated by the tissue alarmins interleukin (IL)-33 and IL-25, these signals do not intrinsically enforce type 2 identity and the mechanisms that maintain type 2 cytokine expression remain unclear. Here we show that allergen-induced IL-33 and IL-25 rapidly induce IL-9, which in turn upregulates the transcriptional repressor Blimp-1 in ILC2s. Blimp-1 sustains type 2 immunity by directly repressing type 1 inflammatory programs, including expression of interferon-γ and tumor necrosis factor. Deletion of Blimp-1 in ILC2s increased type 1 cytokine production and reduced IL-5 and IL-13 expression, eosinophil recruitment and mucus production in the lung. In contrast, IL-9 expression was enhanced in the absence of Blimp-1, leading to increased mast cell recruitment. Together, these findings identify Blimp-1 as a key regulator of ILC2 transcriptional fidelity that stabilizes type 2 inflammation while constraining divergent inflammatory programs during allergic responses.
Background: Atypical carcinoid of the thymus is an exceptionally rare neuroendocrine tumor originating from neuroendocrine cells within the thymus. These tumors often present with no symptoms or with nonspecific clinical signs, making early diagnosis particularly challenging. Despite their rarity, atypical carcinoids are clinically significant due to their aggressive nature and relatively poor prognosis. Early detection and appropriate management are therefore crucial to improving patient outcomes. Results: In this report, we present the case of a 64-year-old patient in whom an atypical carcinoid of the thymus was incidentally discovered following a thoracic computed tomography scan performed for unrelated reasons. Imaging revealed a suspicious anterior mediastinal mass, which was subsequently surgically resected.
Microbiota in clinical cancer immunotherapy.
Gut microbiota research has progressed from mechanistic studies to clinical trials, revealing strong potential to enhance cancer immunotherapy.
Fecal microbiota transplantation, single bacterial strains, and defined microbial consortia are in clinical testing; yet, standardization and implementation remain major challenges.
Donor selection, patient enrollment, microbiota implantation, antibiotic use, safety assessment, and endpoint evaluation each offer distinct opportunities and obstacles.
A ‘4D’ framework, enhancing diversity, diffusion, depth, and delicacy, can guide the optimization of microbiomebased immunotherapy. sciencenewshighlights ScienceMission https://sciencemission.com/microbiota-to-clinical-cancer
Fundamental research has elucidated the indispensable role of gut microbiota in modulating cancer immunotherapy efficacy. Despite promising preclinical findings, few related approaches have reached clinical trials. In this opinion, we provide insights based on current clinical trials using fecal microbiota transplant or specific bacterial strains as adjuvants to enhance immune checkpoint blockade therapy. We also systematically analyze the challenges in trial design, with a focus on donor selection, patient enrollment, implantation procedures, antibiotic use, safety assessment, and endpoint evaluation. Moving forward, we offer a comprehensive ‘4D’ framework (diversity, diffusion, depth, and delicacy) for accelerating the bench-to-bedside translation.
